Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma

Author(s): Roula A. Farah, Soumana C. Nasser, Racha A. Sabbagh, Pele B. Dina, Toufic A. Eid

Journal Name: Current Drug Therapy

Volume 6 , Issue 2 , 2011

Become EABM
Become Reviewer
Call for Editor


Refractory soft tissue sarcomas carry a poor prognosis and limited treatment options require the use of new chemotherapeutic agents. We report the case of an eight year old boy with non metastatic alveolar rhabdomyosarcoma of the right forearm (Group 3, Stage III). After treatment failure of several chemotherapeutic regimens and progression of his disease, Trabectedin was administered at 1.3 mg/m2/dose intravenously over 24 hours for two cycles. The patients quality of life improved as noted by a significant decrease in opiate requirements and ability to tolerate oral intake. The drug was well tolerated with the exception of transient neutropenia.

Keywords: ET-743, pediatric solid tumors, refractory sarcoma, Trabectedin, neutropenia, diagnosis, chemotherapeutic agents, palliative tumor, osteosarcoma, dose limiting toxicity

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [97 - 99]
Pages: 3
DOI: 10.2174/157488511795304912
Price: $65

Article Metrics

PDF: 4